European Centre for Disease Prevention and Control (2023) Antimicrobial resistance in the EU/EEA (EARS-Net) -Annual Epidemiological Report 2022. ECDC, Stockholm

Google Scholar 

Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Onate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltran SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordonez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, Evans S, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler VG Jr., Doi Y, van Duin D, Satlin MJ, Antibacterial Resistance Leadership G, Multi-Drug Resistant Organism Network I (2023) Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe 4(3):e159–e170. https://doi.org/10.1016/S2666-5247(22)00329-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofino E, Sanchez-Diener I, Cortes-Lara S, Lopez-Causape C, Cabot G, Bou G, Martinez-Martinez L, Oliver A, Group G-SRPS (2020) Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic beta-lactam-resistant mutants. Antimicrob Agents Chemother 64(2). https://doi.org/10.1128/AAC.02165-19

Wang L, Zhang X, Zhou X, Yang F, Guo Q, Wang M (2023) Comparison of in vitro activity of ceftazidime-avibactam and imipenem-relebactam against clinical isolates of Pseudomonas aeruginosa. Microbiol Spectr 11(3):e0093223. https://doi.org/10.1128/spectrum.00932_23

Article  PubMed  Google Scholar 

Karlowsky JA, Lob SH, Raddatz J, DePestel DD, Young K, Motyl MR, Sahm DF (2021) In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-negative bacillidifficultficutreat-resistancestance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance trends, United States 2015–2017. Clin Infect Dis 72(12):2112–2120. https://doi.org/10.1093/cid/ciaa381

Article  CAS  PubMed  Google Scholar 

Karlowsky JA, Lob SH, Chen WT, DeRyke CA, Siddiqui F, Young K, Motyl MR, Sahm DF (2023) In vitro activity of imipenem/relebactam against non-Morganellaceae enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017–2020. Int J Antimicrob Agents 62(3):106900. https://doi.org/10.1016/j.ijantimicag.2023.106900

Article  CAS  PubMed  Google Scholar 

Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF (2019) Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17. J Antimicrob Chemother 74(8):2284–2288. https://doi.org/10.1093/jac/dkz191

Article  CAS  PubMed  Google Scholar 

Mushtaq S, Meunier D, Vickers A, Woodford N, Livermore DM (2021) Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. J Antimicrob Chemother 76(2):434–442. https://doi.org/10.1093/jac/dkaa456

Article  CAS  PubMed  Google Scholar 

Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. https://doi.org/10.1093/cid/ciae403

Article  PubMed  Google Scholar 

Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, Pulcini C, Garnacho-Montero J, Seme K, Tumbarello M, Lindemann PC, Gandra S, Yu Y, Bassetti M, Mouton JW, Tacconelli E, Rodriguez-Bano J (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 28(4):521–547. https://doi.org/10.1016/j.cmi.2021.11.025

Article  CAS  PubMed  Google Scholar 

The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, valid from 2024-01-01. http://www.eucast.org

Hakvoort H, Bovenkamp E, Greenwood-Quaintance KE, Schmidt-Malan SM, Mandrekar JN, Schuetz AN, Patel R (2020) Imipenem-Relebactam susceptibility testing of Gram-negative bacilli by agar dilution, disk diffusion, and gradient strip methods compared with broth microdilution. J Clin Microbiol 58(10). https://doi.org/10.1128/JCM.00695_20

Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL, National Institutes of Health Antimicrobial Resistance Outcomes Research I (2018) Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis 67(12):1803–1814. https://doi.org/10.1093/cid/ciy378

Article  PubMed  PubMed Central  Google Scholar 

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281. https://doi.org/10.1111/j.1469-0691.2011.03570.x

Article  CAS  PubMed  Google Scholar 

Performance standards for antimicrobial susceptibility testing 34th ed. CLSI standard M100 Clinical and Laboratory standards institute, Wayne, PA (2024). Clinical and Laboratory Standards Institute, Wayne, PA

Grosjean M, Tazrout S, Bour M, Triponey P, Muller C, Jeannot K, Plsiat P (2021) Reassessment of the cooperativity between efflux system MexAB-OprM and cephalosporinase AmpC in the resistance of Pseudomonas aeruginosa to beta-lactams. J Antimicrob Chemother 76(2):536–539. https://doi.org/10.1093/jac/dkaa462

Article  CAS  PubMed  Google Scholar